18 reports

  • Mar 10, 2017: Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

As you know, DNAbilize& tradeis a proprietary antisense and neutral lipid technology that enables systemic delivery of nucleic acid therapeutics.

  • Antisense Technology
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.
  • Deal in Brief
  • Advisor Information Company Being Advised

ISIS-SMNRx is based on antisense technology platform.

  • Antisense Technology
  • United States
  • Company
  • Company Financials
  • Ionis Pharmaceuticals, Inc.
  • PARTNERSHIPS
  • Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For US$2.04 Million

The therapeutic candidate is developed based on antisense technology.

  • Antisense Technology
  • Pharmaceutical
  • Therapy
  • Australia
  • Antisense Therapeutics Limited
  • Feb 21, 2017: Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

As you know, DNAbilize& tradeis a proprietary antisense and neutral lipid technology that enables systemic delivery of nucleic acid therapeutics.

  • Antisense Technology
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.

ISIS-SMNRx is based on antisense technology platform.

  • Antisense Technology
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Biogen Idec Inc.
  • ATESIDORSEN SODIUM - DRUG PROFILE

The drug candidate is based on antisense technology.

  • Antisense Technology
  • Eye Disease
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • PIPELINE BY NOVARTIS AG, H1 2017

The company offers antisense technology based drugs that treat aggressive tumor diseases.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH
  • ATESIDORSEN SODIUM - DRUG PROFILE

The drug candidate is based on antisense technology.

  • Antisense Technology
  • Therapy
  • United States
  • World
  • Product Initiative
  • PIPELINE BY GENZYME CORP, H2 2018

The company offers antisense technology based drugs that treats aggressive tumor diseases.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH
  • disorder acromegaly
  • ATESIDORSEN SODIUM - DRUG PROFILE

The drug candidate is based on antisense technology.

  • Antisense Technology
  • Eye Disease
  • Type 2 Diabetes
  • United States
  • Product Initiative

Further key findings from the report suggest: • Antisense RNA technology accounted for the largest share in market revenue in 2017 owing to advantages associated with this technology over RNA interference • Based on the triggering of RNA molecules, this

  • Antisense Technology
  • RNAi Technology
  • Therapy
  • United States
  • Market Size
  • PIPELINE BY GENZYME CORP, H1 2018

The company offers antisense technology based drugs that treats aggressive tumor diseases.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH

Further key findings from the report suggest: • RNA interference technology accounted for the largest share in market revenue in 2016 owing to advantages associated with this technology over antisense technology • Based on the triggering of RNA molecules this

  • Antisense Technology
  • RNAi Technology
  • Therapy
  • United States
  • Market Size
  • Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products

It is based on antisense technology platform.

  • Antisense Technology
  • Pharmaceutical
  • United States
  • Company Operations
  • Ionis Pharmaceuticals, Inc.

ISIS-SOD##Rx is based on antisense technology platform.

  • Antisense Technology
  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • ATESIDORSEN SODIUM - DRUG PROFILE

It is based on recombinant DNA technology.

  • Antisense Technology
  • Ophthalmology
  • Therapy
  • Type 2 Diabetes
  • Product Initiative
  • ATL-1101
  • ATL-1101 - DRUG PROFILE

The drug candidate is developed using antisense technology.

  • Antisense Technology
  • Insulin
  • Lung Cancer
  • United States
  • Product Initiative

The company offers antisense technology based drugs that treat aggressive tumor diseases.

  • Antisense Technology
  • Cell Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.